By Rob Curran
Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%.
The drug wholesaler formerly known as AmerisourceBergen logged earnings of $717.9 million, or $3.68 a share, for the fiscal second quarter ended in March, down from $420.8 million, or $2.09 a share, a year earlier.
Stripping out certain one-time items, Cencora's adjusted earnings were $4.42 a share, topping the average Wall Street target of $4.11 a share.
Revenue rose 10% to $75.45 billion, just shy of the mean analyst estimate of $75.68 billion.
Sales growth was particularly strong in its U.S. health-care unit, partly due to rising demand for glucagon-like peptide 1 inhibitors, the blockbuster class of drugs that includes Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Cencora also noted strong demand for specialty products from physicians' offices and other sources.
Cencora boosted its forecast for adjusted earnings per share for the fiscal year ending in September to between $15.70 and $15.95 from a prior estimated range of $15.30 to $15.60.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
May 07, 2025 07:39 ET (11:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。